Home›Stock Screener›Akums Drugs & Pharma›Quarterly Results

Akums Drugs & Pharma Quarterly Results

Latest Quarter Net Profit
₹81 Cr
QMar 2026
Quarterly Results

Akums Drugs & Pharma quarterly results. In Mar 2026, Akums Drugs & Pharma (AKUMS) reported revenue ₹1,193 Cr and net profit ₹81 Cr — revenue +10.4% YoY. Check AKUMS market cap trends to track the company's total market size over time.

AKUMS Quarterly Results — Revenue, Profit & EPS Highlights

Akums Drugs & Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Review Akums Drugs & Pharma P/E valuation to evaluate earnings-based valuation against sector peers.

  • Revenue of ₹1,193 Cr in Mar 2026 (-0.3% vs Jun 2026, +10.4% vs Mar 2025)
  • Net Profit of ₹81 Cr in Mar 2026 (-19.8% vs Jun 2026, -46.0% vs Mar 2025)
  • EBITDA of ₹185 Cr in Mar 2026 (-9.8% vs Jun 2026)
  • Operating Margin of 13.0% in Mar 2026 (-2.0pp vs Jun 2026)
  • Earnings Per Share of ₹5.53 in Mar 2026 (-15.3% vs Jun 2026)

Akums Drugs & Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS

AKUMS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2026 Jun 2026 Sept 2025 Mar 2025 Jun 2025 QoQ YoY
Revenue (₹ Cr) 1,193 1,197 1,050 1,081 1,051 -0.3% 10.4%
Net Profit (₹ Cr) 81 101 43 150 65 - -
EBITDA (₹ Cr) 185 205 127 120 156 - -
EPS (₹) 5.53 6.53 2.66 9.64 4.15 - -
Operating Margin (%) 13.0% 15.0% 9.0% 9.0% 13.0% - -

AKUMS Share Price Trend — 1-Year Movement Across Quarterly Results

Akums Drugs & Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit AKUMS screener.

Profitability Ratios

Profit Margin 6.8%
EBITDA Margin 15.5%
Operating Margin 13.0%
ROE (Annual) 9.7%

Balance Sheet Highlights

Total Assets ₹5,447 Cr
Total Equity ₹3,331 Cr
Current Assets ₹3,560 Cr
Current Liabilities ₹1,021 Cr

Cash Flow Analysis

Operating Cash Flow ₹1,181 Cr
Investing Cash Flow ₹-930 Cr
Financing Cash Flow ₹34 Cr
Net Cash Flow ₹285 Cr

Current Market Data

Current Price ₹786.70
Exchange NSE
Last Updated Oct 08, 2026

Revenue Trend (₹ Cr)

Mar 2025 1,081
Sept 2025 1,050
Jun 2026 1,197
Mar 2026 1,193

Net Profit Trend (₹ Cr)

Mar 2025 150
Sept 2025 43
Jun 2026 101
Mar 2026 81

Operating Margin Trend (%)

Mar 2025 9.0%
Sept 2025 9.0%
Jun 2026 15.0%
Mar 2026 13.0%

AKUMS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Akums Drugs & Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026 		₹432,120.23 Cr 1759.8 15,018 2,710 -5.6% - 18.0% 155.7
Divis Laboratories
Mar 2026 		₹244,124.91 Cr 9361.0 2,986 751 -5.0% - 25.2% 330.7
Torrent Pharmaceuti…
Mar 2026 		₹188,719.51 Cr 4617.1 4,111 364 +27.7% +42.2% 8.9% 401.1
Zydus Life Science
Mar 2026 		₹113,615.69 Cr 1112.0 7,569 1,341 -4.3% - 17.7% 87.9
Laurus Labs
Mar 2026 		₹109,629.35 Cr 1997.9 1,823 282 -10.5% - 15.5% 386.4
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores